Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
Hartzell
Joshua D
JD
US Army, Infectious Diseases Service, Walter Reed Army Medical Center, Bldg. 2, Ward 63, 6900 Georgia Ave. NW, Washington, DC 20307, USA. joshua.hartzell@amedd.army.mil
Neff
Robert
R
Ake
Julie
J
Howard
Robin
R
Olson
Stephen
S
Paolino
Kristopher
K
Vishnepolsky
Mark
M
Weintrob
Amy
A
Wortmann
Glenn
G
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D003091:Colistin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008297:Male; D051437:Renal Insufficiency / Q000139:chemically induced*; D014481:United States; D028761:Withholding Treatment; D055815:Young Adult
D000900:Anti-Bacterial Agents; C004691:colistinmethanesulfonic acid; D003091:Colistin